Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BISCAY: Biomarker-Directed Study in MIBC
NCT02546661Phase 1Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2016
- Primary completion
- Mar 2020
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 5
01
Overview
Phase 1, randomised, open-label trial of durvalumab, fexagratinib, olaparib, adavosertib, vistusertib and 2 more in muscle-invasive bladder cancer (MIBC) (8 arms), sponsored by AstraZeneca. Primary endpoints: Adverse Events, Change from baseline in clinical chemistry parameters and 1 more. Started Dec 2016; status: active, not recruiting.
02
Drugs
durvalumabfexagratinibolaparibadavosertibvistusertib
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT02546661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02546661.